Azenta (AZTA) has put a tough quarter on the table, with Q2 2026 revenue of US$144.8 million and a basic EPS loss of US$3.41, alongside net income from continuing operations showing a loss of US$157.0 million. The company has seen quarterly revenue move from US$143.4 million in Q2 2025 to US$158.0 million in Q4 2025 and then to US$144.8 million in Q2 2026. EPS has swung from a loss of US$0.40 in Q2 2025 to a profit of US$1.12 in Q4 2025 and back to a loss of US$3.41 in the latest quarter, which puts the focus squarely on how sustainable margins really are.

See our full analysis for Azenta.

With the latest numbers on the table, the next step is to see how this earnings profile lines up with the key narratives around Azenta's growth potential and risk profile that many investors follow.

Losses Spike To US$157 Million Despite Steady Sales

• Net income from continuing operations moved from a loss of US$5.2 million in Q1 2026 to a much larger loss of US$157.0 million in Q2 2026. Revenue over the same two quarters stayed in a relatively tight range, from US$148.6 million to US$144.8 million.
• Bears highlight that this kind of earnings volatility, with EPS swinging from a profit of US$1.12 in Q4 2025 to a loss of US$3.41 in Q2 2026, fits their concern that cost issues and operational hiccups can keep margins under pressure even when demand for biorepositories and multiomics is described as healthy.
  • The bearish narrative also points to quality remediation in automated stores, where rework costs in the US$3 million to US$5 million range are cited as a drag on profitability. This lines up directionally with the sharp move in net income into a US$157.0 million loss.
  • Critics argue that until efficiency programs like the Azenta Business System and lab automation show through in more stable earnings, swings between small profits and large losses, as seen across 2025 and into 2026, leave the bearish case intact.

Bears looking at the latest move into a US$157 million loss see plenty of support for their caution around margins and execution risks, especially while earnings remain so volatile even on relatively stable revenue.

🐻 Azenta Bear Case

Trailing Twelve Months Still Unprofitable At US$110.9 Million Loss

• On a trailing twelve month basis to Q2 2026, Azenta recorded total revenue of US$596.5 million and a net loss excluding extra items of US$110.9 million, with earnings from discontinued operations contributing a further US$62.5 million loss.
• Consensus narrative supporters point out that analysts expect earnings to reach US$53.6 million by around 2029 with margins rising from 4.4% to 7.4%. However, the current trailing loss of US$110.9 million and basic EPS of US$2.42 loss show that the business is still some distance from those profitability levels.
  • What stands out is that revenue in the data is described as growing at about 6% a year, which is slower than the referenced 11.3% US market rate. As a result, the bullish expectations for higher margins have to work against both an unprofitable base and more moderate top line growth.
  • Supporters of the balanced view point to cost control efforts such as reported G&A reductions and productivity programs, but the numbers available here only confirm that losses have persisted over the last twelve months, not yet that margin expansion has flowed through to net income.

Valuation Signals Contrast With Loss Making Profile

• Azenta is shown trading on a P/S of 1.4x versus a US life sciences industry average of 3.4x and a peer average of 4.8x, while a DCF fair value of US$45.57 is materially above the current share price of US$18.38.
• Bulls argue that these valuation gaps, combined with analysts forecasting very large percentage earnings growth and a move to profitability within three years, support a constructive view even though the latest trailing twelve month figures still show a US$110.9 million loss.
  • What is supportive for the bullish side is that revenue over the last year of about US$596.5 million sits against a market value that implies a lower sales multiple than both industry and peer averages according to the data. Bulls see this as mispricing relative to long term earnings potential.
  • At the same time, the fact that losses have narrowed over five years at about 12.2% per year in the provided analysis helps bulls frame the current unprofitable status as part of a longer process of improvement, even though recent quarters like Q2 2026 still show sizeable headline losses.

If you want to see how those growth and margin expectations stack up against detailed fair value work and scenario analysis, it is worth looking at the more optimistic narrative that ties this pricing gap to future earnings power 🐂 Azenta Bull Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Azenta on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If this mix of bullish and bearish narratives feels conflicted, that is exactly why your own judgment matters, so take a closer look at the underlying figures and context. To see what optimistic investors are focusing on, review the company’s 3 key rewards

See What Else Is Out There

Azenta is still loss making with US$157.0 million in quarterly losses and a US$110.9 million trailing loss, which keeps earnings volatility and execution risk firmly in focus.

If that level of uncertainty makes you uneasy, consider using the 74 resilient stocks with low risk scores to quickly narrow in on companies where earnings and balance sheets look more resilient right now.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.